Skip to main content

Table 2 Changes of variables related with HbA 1c , FBG, and P2hBG after 24-week treatment

From: Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

  Baseline (mean ± s.d) 24 weeks (mean ± s.d) Mean changes from baseline (95% CI) Difference in mean change (95% CI) ΔDifference in mean change (95% CI)
HbA1c (%)
Vildagliptin 8.75 ± 1.15 7.41 ± 1.43 -1.34 (-2.03, -0.64)**   
Saxagliptin 8.86 ± 1.13 7.65 ± 1.41 -1.21 (-1.91, -0.51)** 0.13 (-0.66, 0.40)  
Sitagliptin 8.54 ± 1.19 7.47 ± 1.42 -1.07 (-1.64, -0.50)** 0.27 (-0.80, 0.26) 0.14 (-0.67, 0.39)
FBG (mmol/L)
Vildagliptin 8.79 ± 1.80 6.35 ± 1.57 -2.44 (-3.01, -1.87)**   
Saxagliptin 8.36 ± 2.04 6.53 ± 1.92 -1.83 (-2.13, -1.53)** 0.61 (0.30, 0.92)##  
Sitagliptin 8.22 ± 1.77 6.73 ± 1.69 -1.49 (-1.69, -1.29)** 0.95 (0.64, 1.26)## 0.34 (0.03, 0.65)Δ
P2BG (mmol/L)
Vildagliptin 11.98 ± 2.46 8.27 ± 2.28 -3.71 (-4.16, -3.26)**   
Saxagliptin 11.77 ± 3.07 8.36 ± 2.70 -3.41 (-4.33, -2.49)** 0.30 (-0.32, 0.92)  
Sitagliptin 10.98 ± 2.93 7.82 ± 2.58 -3.16 (-4.03, -2.29)** 0.55 (-0.07, 1.17) -0.25 (-0.37, 0.87)
  1. 63 subjects in Vildagliptin-added group, 66 subjects in Saxagliptin-added group and 61 subjects in Sitagliptin-added group were analyzed; Difference in mean change calculated as Saxagliptin minus Vildagliptin or Sitagliptin minus Vildagliptin; ΔDifference in mean change calculated as Sitagliptin minus Saxagliptin. CI: confidence interval; **p < 0.01 for mean change from baseline in Vildagliptin, Saxagliptin and Sitagliptin; ##p < 0.01 for the between-treatment difference from Vildagliptin; Δp < 0.05, ΔΔp < 0.01 for the between-treatment difference from Saxagliptin.